Vincent Romanet

JAK–STAT Pathway Activation in Malignant and Nonmalignant Cells Contributes to MPN Pathogenesis and Therapeutic Response

Maria Kleppe, Minsuk Kwak, Priya Koppikar et al. · Cancer Discovery · 2015 · 315 citations · Full text

Medicine, Hematology, Pharmacology +17

JAK2/STAT5 Inhibition Circumvents Resistance to PI3K/mTOR Blockade: A Rationale for Cotargeting These Pathways in Metastatic Breast Cancer

Adrian Britschgi, Rita Andraos, Heike Brinkhaus et al. · Cancer Cell · 2012 · 242 citations · Full text

Medicine, Oncology, Pharmacology +16

Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition

Oliver Weigert, Andrew A. Lane, Liat Bird et al. · The Journal of Experimental Medicine · 2012 · 162 citations · Full text

Medicine, Oncology, Pharmacology +14

CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms

Sara C. Meyer, Matthew D. Keller, Sophia Chiu et al. · Cancer Cell · 2015 · 155 citations

Medicine, Pharmacology, Pharmacotherapy +13

Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers

Emilie A. Chapeau, Laurent Sansregret, Giorgio Giacomo Galli et al. · Nature Cancer · 2024 · 132 citations · Full text

Medicine, Cancer Biology, Oncology +15